Brought to you by 
MediGene acquires Munich Biotech AG
27 Sep 2004
Executive Summary
MediGene AG (cancer drugs) has acquired Munich Biotech AG (private cancer therapeutics company that recently filed for insolvency) for stock that is valued at €12.5mm ($15.3mm); it will not assume any liabilities.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Large Molecule
- Liposomes
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MediGene acquires Munich Biotech AG
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice